4-(3,5-dibromophenyl)-4-hydroxy-1-tert-butyloxycarbonylpiperidine | 185843-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3,5-dibromophenyl)-4-hydroxy-1-tert-butyloxycarbonylpiperidine
• 英文别名: Tert-butyl 4-(3,5-dibromophenyl)-4-hydroxypiperidine-1-carboxylate
• CAS: 185843-79-2
• 化学式: C₁₆H₂₁Br₂NO₃
• 分子量: 435.156
• InChiKey: RCEBHZSVAQLECC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,5-dibromophenyl)-4-hydroxy-1-tert-butyloxycarbonylpiperidine 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 4-(3,5-Dibromophenyl)-4-hydroxy-piperidine hydrochloride
  参考文献：
  名称：

  Synthesis of high-specific activity tritium and optically pure [14C]CP-101,606. Enantioselective crystallization of a radiochemically racemic mixture

  摘要：

  The syntheses of racemic, high-specific activity tritium and optically pure, carbon-14 labelled CP-101,606 is described. The tritium labelled material was prepared at 35.6 Ci/mmol by hydrogenolysis of the dibromo analog (5) under bar. In the carbon-14 synthesis, the radiolabel was introduced in the final carbon-carbon bond forming step by alkylation of the readily available aminoketone (8) under bar with [C-14]methyl iodide. Three-selective sodium borohydride reduction of the ketone and deprotection of the phenol gave racemic [C-14]CP-101,606. Enantiomerically pure (+)-[C-14]CP-101,606 was obtained by addition of optically pure, unlabelled drug and directly recrystallizing the enantiomerically enriched, but radiochemically racemic, mixture.

  DOI：

  10.1002/(sici)1099-1344(199712)39:12<973::aid-jlcr40>3.0.co;2-o
• 作为产物：
  描述：

  1,3,5-三溴苯 、 N-叔丁氧羰基-4-哌啶酮 在 正丁基锂 作用下， 生成 4-(3,5-dibromophenyl)-4-hydroxy-1-tert-butyloxycarbonylpiperidine
  参考文献：
  名称：

  Synthesis of high-specific activity tritium and optically pure [14C]CP-101,606. Enantioselective crystallization of a radiochemically racemic mixture

  摘要：

  The syntheses of racemic, high-specific activity tritium and optically pure, carbon-14 labelled CP-101,606 is described. The tritium labelled material was prepared at 35.6 Ci/mmol by hydrogenolysis of the dibromo analog (5) under bar. In the carbon-14 synthesis, the radiolabel was introduced in the final carbon-carbon bond forming step by alkylation of the readily available aminoketone (8) under bar with [C-14]methyl iodide. Three-selective sodium borohydride reduction of the ketone and deprotection of the phenol gave racemic [C-14]CP-101,606. Enantiomerically pure (+)-[C-14]CP-101,606 was obtained by addition of optically pure, unlabelled drug and directly recrystallizing the enantiomerically enriched, but radiochemically racemic, mixture.

  DOI：

  10.1002/(sici)1099-1344(199712)39:12<973::aid-jlcr40>3.0.co;2-o

文献信息

• Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and
  申请人：Pfizer Inc.

  公开号：US06046213A1

  公开（公告）日：2000-04-04

  This invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, wherein: (a) R.sup.2 and R.sup.5 are taken separately and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently hydrogen, (C.sub.1 -C.sub.6) alkyl, halo, CF.sub.3, OH or OR.sup.7 and R.sup.5 is methyl or ethyl; or (b) R.sup.2 and R.sup.5 are taken together, forming a chroman-4-ol ring, and R.sup.1, R.sup.3 and R.sup.4 are each independently hydrogen, (C.sub.1 -C.sub.6) alkyl, halo, CF.sub.3, OH or OR.sup.7 ; and R.sup.6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo(3.2.1)octanyl derivative; provided that (a) when R.sup.2 and R.sup.5 are taken separately, at least one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is not hydrogen; and (b) when R.sup.2 and R.sup.5 are taken together, at least one of R.sup.1, R.sup.3 and R.sup.4 is not hydrogen; pharmaceutical compositions thereof; and methods of treating mammals suffering from stroke, spinal cord trauma, traumatic brain injury, multiinfarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, Huntington's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia, psychotic conditions, drug addictions, migraine, hypoglycemia, anxiolytic conditions, urinary incontinence and an ischemic event arising from CNS surgery, open heart surgery or any procedure during which the function of the cardiovascular system is compromised with a compound of formula (I) hereinabove or a pharmaceutically acceptable salt thereof. ##STR1##

  这项发明涉及化合物的结构式(I)，或其药学上可接受的酸盐，其中：(a) R.sup.2和R.sup.5分别取，R.sup.1，R.sup.2，R.sup.3和R.sup.4各自独立地为氢，(C.sub.1 -C.sub.6)烷基，卤素，三氟甲基，羟基或OR.sup.7，R.sup.5为甲基或乙基；或者(b) R.sup.2和R.sup.5取在一起，形成一个色苷-4-醇环，R.sup.1，R.sup.3和R.sup.4各自独立地为氢，(C.sub.1 -C.sub.6)烷基，卤素，三氟甲基，羟基或OR.sup.7；而R.sup.6为取代的哌啶基，吡咯啉基或8-氮杂双环(3.2.1)辛基衍生物；条件是(a)当R.sup.2和R.sup.5分开取时，R.sup.1，R.sup.2，R.sup.3和R.sup.4中至少有一个不是氢；(b)当R.sup.2和R.sup.5取在一起时，R.sup.1，R.sup.3和R.sup.4中至少有一个不是氢；其中包括其药物组成；以及治疗患有中风，脊髓创伤，创伤性脑损伤，多梗塞性痴呆，中枢神经系统退行性疾病如阿尔茨海默病，老年性阿尔茨海默病，亨廷顿病，帕金森病，癫痫，肌萎缩侧索硬化，疼痛，艾滋病痴呆，精神病症，药物成瘾，偏头痛，低血糖，抗焦虑症状，尿失禁以及由中枢神经系统手术，开心脏手术或心血管系统功能受损的任何过程引起的缺血事件的方法，使用上述的结构式(I)中的化合物或其药学上可接受的盐。
• Combinations for the treatment of parkinsonism containing selective NMDA antagonists
  申请人：Pfizer Inc.

  公开号：US06258827B1

  公开（公告）日：2001-07-10

  This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex. This invention also relates to pharmaceutical compositions containing the synergistic combination.

  本发明涉及一种治疗帕金森病的方法，通过给患有帕金森病的哺乳动物使用前脑选择性NMDA拮抗剂和一种能够增加来自丘脑腹侧核对皮层的兴奋性反馈的化合物的组合来治疗。本发明还涉及含有这种协同组合的药物组合物。
• NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES
  申请人：PFIZER INC.

  公开号：EP0777652B1

  公开（公告）日：2003-06-25
• COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS
  申请人：PFIZER INC.

  公开号：EP0828513B1

  公开（公告）日：2004-01-21
• US6046213A
  申请人：——

  公开号：US6046213A

  公开（公告）日：2000-04-04